Clinical trial
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
NCT00129337 · Peregrine Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00129337 |
|---|---|
| Title | Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies |
| Official title | A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients With Refractory Advanced Solid Tumor Malignancies |
| Lead sponsor | Peregrine Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | Bavituximab |
| Enrollment | 28 |
| Start date | Jun 1, 2005 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Aug 11, 2005 |
| Last update posted | Mar 1, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: